These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 25385586)

  • 1. Bispecific antibody generated with sortase and click chemistry has broad antiinfluenza virus activity.
    Wagner K; Kwakkenbos MJ; Claassen YB; Maijoor K; Böhne M; van der Sluijs KF; Witte MD; van Zoelen DJ; Cornelissen LA; Beaumont T; Bakker AQ; Ploegh HL; Spits H
    Proc Natl Acad Sci U S A; 2014 Nov; 111(47):16820-5. PubMed ID: 25385586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
    Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
    MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of dual-variable-domain immunoglobulin molecules for dual-specific targeting.
    Gu J; Ghayur T
    Methods Enzymol; 2012; 502():25-41. PubMed ID: 22208980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PSMA-targeted bispecific Fab conjugates that engage T cells.
    Patterson JT; Isaacson J; Kerwin L; Atassi G; Duggal R; Bresson D; Zhu T; Zhou H; Fu Y; Kaufmann GF
    Bioorg Med Chem Lett; 2017 Dec; 27(24):5490-5495. PubMed ID: 29126850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemically generated IgG2 bispecific antibodies through disulfide bridging.
    Patterson JT; Gros E; Zhou H; Atassi G; Kerwin L; Carmody L; Zhu T; Jones B; Fu Y; Kaufmann GF
    Bioorg Med Chem Lett; 2017 Aug; 27(16):3647-3652. PubMed ID: 28720505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The assembly of single domain antibodies into bispecific decavalent molecules.
    Stone E; Hirama T; Tanha J; Tong-Sevinc H; Li S; MacKenzie CR; Zhang J
    J Immunol Methods; 2007 Jan; 318(1-2):88-94. PubMed ID: 17141798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation of bispecific antibody-protein adducts by site-specific chemo-enzymatic conjugation.
    Bartels L; Ploegh HL; Spits H; Wagner K
    Methods; 2019 Feb; 154():93-101. PubMed ID: 30081077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair.
    Strop P; Ho WH; Boustany LM; Abdiche YN; Lindquist KC; Farias SE; Rickert M; Appah CT; Pascua E; Radcliffe T; Sutton J; Chaparro-Riggers J; Chen W; Casas MG; Chin SM; Wong OK; Liu SH; Vergara G; Shelton D; Rajpal A; Pons J
    J Mol Biol; 2012 Jul; 420(3):204-19. PubMed ID: 22543237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a bispecific antibody tetramerized through hetero-associating peptides.
    Osaki T; Fujisawa S; Kitaguchi M; Kitamura M; Nakanishi T
    FEBS J; 2015 Nov; 282(22):4389-401. PubMed ID: 26337767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bispecific antibodies for cancer therapy.
    Hollander N
    Immunotherapy; 2009 Mar; 1(2):211-22. PubMed ID: 20635943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bispecific antibodies as novel bioconjugates.
    Cao Y; Suresh MR
    Bioconjug Chem; 1998; 9(6):635-44. PubMed ID: 9815155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein design of IgG/TCR chimeras for the co-expression of Fab-like moieties within bispecific antibodies.
    Wu X; Sereno AJ; Huang F; Zhang K; Batt M; Fitchett JR; He D; Rick HL; Conner EM; Demarest SJ
    MAbs; 2015; 7(2):364-76. PubMed ID: 25611120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
    Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
    MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies.
    Yang F; Wen W; Qin W
    Int J Mol Sci; 2016 Dec; 18(1):. PubMed ID: 28036020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. bisFabs: Tools for rapidly screening hybridoma IgGs for their activities as bispecific antibodies.
    Patke S; Li J; Wang P; Slaga D; Johnston J; Bhakta S; Panowski S; Sun LL; Junttila T; Scheer JM; Ellerman DA
    MAbs; 2017 Apr; 9(3):430-437. PubMed ID: 28125314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression and purification of monospecific and bispecific recombinant antibody fragments derived from antibodies that block the CD80/CD86-CD28 costimulatory pathway.
    Dincq S; Bosman F; Buyse MA; Degrieck R; Celis L; de Boer M; Van Doorsselaere V; Sablon E
    Protein Expr Purif; 2001 Jun; 22(1):11-24. PubMed ID: 11388794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition.
    Croasdale R; Wartha K; Schanzer JM; Kuenkele KP; Ries C; Mayer K; Gassner C; Wagner M; Dimoudis N; Herter S; Jaeger C; Ferrara C; Hoffmann E; Kling L; Lau W; Staack RF; Heinrich J; Scheuer W; Stracke J; Gerdes C; Brinkmann U; Umana P; Klein C
    Arch Biochem Biophys; 2012 Oct; 526(2):206-18. PubMed ID: 22464987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bispecific antibody derivatives based on full-length IgG formats.
    Grote M; Haas AK; Klein C; Schaefer W; Brinkmann U
    Methods Mol Biol; 2012; 901():247-63. PubMed ID: 22723106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bispecific antibodies: molecules that enable novel therapeutic strategies.
    Fischer N; Léger O
    Pathobiology; 2007; 74(1):3-14. PubMed ID: 17496428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single variable domain antibody as a versatile building block for the construction of IgG-like bispecific antibodies.
    Shen J; Vil MD; Jimenez X; Zhang H; Iacolina M; Mangalampalli V; Balderes P; Ludwig DL; Zhu Z
    J Immunol Methods; 2007 Jan; 318(1-2):65-74. PubMed ID: 17126853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.